Ontology highlight
ABSTRACT: Background
There is a paucity of data on the role of allogeneic hematopoietic cell transplantation (allo-HCT) in patients with angioimmunoblastic T-cell lymphoma (AITL). Using the CIBMTR registry, we report here the outcomes of AITL patients undergoing an allo-HCT.Methods
We evaluated 249 adult AITL patients who received their first allo-HCT during 2000-2016.Results
The median patient age was 56 years (range?=?21-77). Majority of the patients were Caucasians (86%), with a male predominance (60%). Graft-versus-host disease (GVHD) prophylaxis was predominantly calcineurin inhibitor-based approaches while the most common graft source was peripheral blood (97%). Median follow-up of survivors was 49 months (range?=?4-170 months). The cumulative incidence of grade 2-4 and grade 3-4 acute GVHD at day 180 were 36% (95% CI?=?30-42) and 12 (95% CI?=?8-17), respectively. The cumulative incidence of chronic GVHD at 1 year was 49% (95%CI 43-56). The 1-year non-relapse mortality (NRM) was 19% (95% CI?=?14-24), while the 4-year relapse/progression, progression-free survival (PFS), and overall survival (OS) were 21% (95% CI?=?16-27), 49% (95% CI?=?42-56), and 56% (95% CI?=?49-63), respectively. On multivariate analysis, chemoresistant status at the time of allo-HCT was associated with a significantly higher risk for therapy failure (inverse of PFS) (RR?=?1.73 95% CI?=?1.08-2.77), while KPS ConclusionOur analysis shows that allo-HCT provides durable disease control even in AITL patients who failed a prior auto-HCT and in those subjects with refractory disease at the time of allografting.
SUBMITTER: Epperla N
PROVIDER: S-EPMC6329157 | biostudies-literature | 2019 Jan
REPOSITORIES: biostudies-literature
Epperla Narendranath N Ahn Kwang W KW Litovich Carlos C Ahmed Sairah S Ahmed Sairah S Battiwalla Minoo M Cohen Jonathon B JB Dahi Parastoo P Farhadfar Nosha N Farooq Umar U Freytes Cesar O CO Ghosh Nilanjan N Haverkos Bradley B Herrera Alex A Hertzberg Mark M Hildebrandt Gerhard G Inwards David D Kharfan-Dabaja Mohamed A MA Khimani Farhad F Lazarus Hillard H Lazaryan Aleksandr A Lekakis Lazaros L Murthy Hemant H Nathan Sunita S Nishihori Taiga T Pawarode Attaphol A Prestidge Tim T Ramakrishnan Praveen P Rezvani Andrew R AR Romee Rizwan R Shah Nirav N NN Sureda Ana A Fenske Timothy S TS Hamadani Mehdi M
Journal of hematology & oncology 20190110 1
<h4>Background</h4>There is a paucity of data on the role of allogeneic hematopoietic cell transplantation (allo-HCT) in patients with angioimmunoblastic T-cell lymphoma (AITL). Using the CIBMTR registry, we report here the outcomes of AITL patients undergoing an allo-HCT.<h4>Methods</h4>We evaluated 249 adult AITL patients who received their first allo-HCT during 2000-2016.<h4>Results</h4>The median patient age was 56 years (range = 21-77). Majority of the patients were Caucasians (86%), with a ...[more]